Ennogen, a U.K.-based drug and device maker, reeled in a £30 million ($37.5 million) credit facility that the company will use to expand its international horizons. Santander U.K. is behind the loan ...

Madrigal also expects to reinforce Rezdiffra’s clinical profile—and potentially convert the current accelerated approval to a full nod—with patient outcomes data from the MAESTRO-NASH trial. That ...

In an ongoing battle for dominance in the eyes of healthcare professionals for their work developing heart disease-focused drugs, Novartis has now snatched the top spot from Pfizer, according to a ...

Even after consumer outfit Kenvue split from Johnson & Johnson one year ago, the company has been performing certain services for the pharma and medtech giant as part of a transition process. | Kenvue ...

After a 2023 approval from the FDA, Krystal Biotech has collected more than $95 million from its launch of Vyjuvek, the first treatment for the rare skin disease dystrophic epidermolysis bullo | The ...

In its opening months, after spinning off as a separate business from Novartis, Sandoz is riding the wave of a strong launch of its biosimilar version of AbbVie’s Humira (adalimumab). | After spinning ...